Healthcare
Iovance Biotherapeutics, Inc.(IOVA)
Live Price
Offline$3.78
-2.58% today
1Y Change
+125.86%
Window
Jun 26, 2025 β Jun 17, 2026
- Market Cap
- $1.11B
- Revenue Growth
- +60.6%
- EPS Growth
- +14.8%
- Dividend Yield
- 0.0%
Coverage: 245 bars Β· Jun 26, 2025 β Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Iovance Biotherapeutics, Inc. (IOVA) is a Healthcare stock with a market cap of $1.11B and listed on NASDAQ. The stock last traded around $3.78 and up 125.9% across the available one-year price window (Jun 26, 2025 β Jun 17, 2026). Baseline metrics include revenue growth of +60.6%, EPS growth of +14.8%, a dividend yield of 0.0%. What stands out right now is revenue +60.6%, EPS +14.8%, free cash flow +7.6% with operating margin -153.1% and ROIC -51.5%. Valuation sits in the middle of the pack at price/sales 4.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines IOVA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+60.6% vs +7.6% peer median
Operating Margin
Below sector median
-153.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +60.6% and EPS at +14.8%, with operating margin around -153.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.9% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | β | -2.0% | +5.1% | +15.9% |
2026 Feb 24, 2026 | +18.2% | +1.3% | -0.8% | -4.2% |
2025 Nov 6, 2025 | +13.8% | -0.4% | +4.3% | -4.8% |
Benchmark Edge
IOVA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IOVA
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IOVA Max Drawdown
-54.41%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IOVA and SPY.
Company Overview
Iovance Biotherapeutics, Inc.
NASDAQ Global Market
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'UniversitΓ© de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
- Leadership
- Frederick G. Vogt
- IPO Date
- Oct 15, 2010
- Employees
- 838
- Street Address
- 825 Industrial Road
- Mailing
- San Carlos, CA, 94070
- Region
- San Carlos, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 260 7120
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 4.2
- Price/Book
- 2.0
Growth
- Revenue
- +60.6%
- EPS
- +14.8%
- Free Cash Flow
- +7.6%
Profitability
- Gross Margin
- 97.2%
- Operating Margin
- -153.1%
- Net Margin
- -148.4%
- ROE
- -54.5%
- ROIC
- -51.5%
Balance Sheet
- Debt/Equity
- 0.07
- Current Ratio
- 3.20
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.